SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
COPENHAGEN, Denmark, July 14, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that the upgrade of its production facility was completed this week. The upgrade has been in process the last 6 weeks and has included an additional storage container, improved mixing machines and upscale filtration unit. The upgrade allows Vilact Bio Inc to increase its production of its Lactoactive® molecule and output with an estimated 300% which the company anticipates will be needed as a part of the new range of products that is being launched this fall.
“This is another important step in our evolution as a skin care and Biotech Company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Find out about Vilact on instagram https://www.instagram.com/vilact_com/ and facebook https://da-dk.facebook.com/skincare.vilact/.
Vilacto Bio Inc. The Seagram Building 375 Park Avenue, Suite 2607 New York City, NY 10152 Gert Andersen Phone: +1 646-893-7895 [email protected] www.vilactobio.com Source: Vilacto Bio Inc.
